Ultramicronized palmitoylethanolamide (PEA-um®) in the treatment of idiopathic pulmonary fibrosis

    loading  Checking for direct PDF access through Ovid

Abstract

Pulmonary fibrosis is a chronic condition characterized by progressive scarring of lung parenchyma. The aim of this study was to examine the effects of an ultramicronized preparation of palmitoylethanolamide (PEA-um®), an endogenous fatty acid amide, in mice subjected to idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis was induced in male mice by a single intratracheal administration of saline with bleomycin sulphate (1 mg/kg body weight) in a volume of 100 μL. PEA-um® was injected intraperitoneally at 1, 3 or 10 mg/kg 1 h after bleomycin instillation and daily thereafter. Animals were sacrificed after 7 and 21 days by pentobarbitone overdose. One cohort of mice was sacrificed after seven days of bleomycin administration, followed by bronchoalveloar lavage and determination of myeloperoxidase activity, lung edema and histopathology features. In the 21-day cohort, mortality was assessed daily, and surviving mice were sacrificed followed by the above analyses together with immunohistochemical localization of CD8, tumor necrosis factor-α, CD4, interleukin-1β, transforming growth factor-β, inducible nitric oxide synthase and basic fibroblast growth factor. Compared to bleomycin-treated mice, animals that received also PEA-um® (3 or 10 mg/kg) had significantly decreased weight loss, mortality, inflammation, lung damage at the histological level, and lung fibrosis at 7 and 21 days. PEA-um® (1 mg/kg) did not significantly inhibit the inflammation response and lung fibrosis. This study demonstrates that PEA-um® (3 and 10 mg/kg) reduces the extent of lung inflammation in a mouse model of idiopathic pulmonary fibrosis.

Related Topics

    loading  Loading Related Articles